COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00046696
Recruitment Status : Completed
First Posted : October 2, 2002
Last Update Posted : May 20, 2015
Information provided by:

Brief Summary:
A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: NM-3 Phase 1

Detailed Description:
This is a non-randomized, open-label, Phase I study. A modified Fibonacci dose escalation will be used to determine the MTD for subsequent Phase II trials. Study duration is expected to be 12 to 18 months. Patients with a histological or cytological diagnosis of a solid tumor who have failed standard therapy or for whom no standard therapy exists are enrolled. If there is no dose limiting toxicities and if patients meet the inclusion criteria and have none of the exclusion criteria of the protocol, they will receive further cycles of therapy if there is no evidence of disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I and Pharmacokinetic Study of NM-3 Administered Orally Once or Twice Daily on Five Consecutive Days and Repeated Weekly for Six Weeks Every Eight Weeks in Patients With Advanced Solid Tumors.
Study Start Date : May 2001
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Primary Outcome Measures :
  1. MTD of NM-3 is the dose at which less than or equal to 1 of 6 patients experiences a DLT

Secondary Outcome Measures :
  1. Anti-tumor activity
  2. VEGF and bFGF in urine, plasma and serum
  3. Circulating endothelial cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients at least 18 years of age.
  • All patients must have an advanced solid tumor that has failed standard therapy or for which no standard therapy exists.
  • Histological or cytological diagnosis of a malignant solid tumor.
  • Measurable or non-measurable disease.
  • Any chemotherapy, radiotherapy, or major surgery at least 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). Patients must have recovered from the toxic effects of any prior therapy.
  • Karnofsky performance status index greater than or equal to 80.
  • Must have adequate organ and immune system function according to the study design, obtained less than or equal to 7-days prior to treatment with NM-3.
  • Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of study enrollment. Men and women with reproductive potential must use an effective contraceptive method while enrolled in this study and for 3 months after the patient has completed study.
  • Patient must be able to swallow.
  • Signed, written informed consent from patient or guardian.
  • Estimated life expectancy of at least 12 weeks.

Exclusion Criteria:

  • Known sensitivity to study drug or its analogs.
  • Treatment with any investigational therapy within the preceding 4 weeks.
  • Patients with hematological malignancies including leukemia, lymphoma, or multiple myeloma.
  • Active and uncontrolled infection.
  • Psychiatric disorders, alcohol or chemical abuse that would interfere with consent or follow-up.
  • Uncontrolled congestive heart failure or angina.
  • Pregnancy or lactation.
  • Any other severe concurrent disease, which as judged by the investigator, would make the patient inappropriate for entry into this study.
  • Patients with active gastrointestinal bleeding or ulceration, unhealed wounds or active thrombosis.
  • Patients who are on anticoagulant therapy or taking aspirin, nonsteroidal anti-inflammatory drugs, unfractionated heparin, low molecular weight heparin, danaproid, thrombolytic agents, anti-platelet antibodies, glycoprotein IIb, IIIa antagonists, H2 blockers, or proton pump inhibitors.
  • Brain or leptomeningeal metastases.
  • Patients known to be HIV positive or who have an AIDS-related illness.
  • Patients with a history of gastrointestinal bleeding from varices, arteriovenous malformations, Osler Weber Rendu syndrome, polyps, prior surgery, or gastric ulcerations. Patients who had bleeding not associated with a coagulopathy after surgery or gastric ulceration and who have no further bleeding or recurrence of their ulcers for more than one year are eligible for this study.
  • Patients with a total accumulated doxorubicin or equivalent dose over 450 mg/m2.
  • Patients with more than 1 risk factor, where a risk factor is defined as any one of the following (1-7):1. prior anthracyclines larger than 300 mg/m2 doxorubicin equivalent.2.mediastinum/left breast irradiation. 3.history of arterial hypertension (systolic blood pressure greater than 140 or diastolic blood pressure greater than 90, or receiving anti-hypertensive treatment).4. obesity (body mass index (BMI)[30]).5. diabetes mellitus (fasting plasma glucose level greater than 126 mg/dL American Diabetes Association (ADA) guidelines).6. smoking (any smoking in the month prior to study entry).7. hypercholesterolemia (greater than 240 mg/dL).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00046696

Layout table for location information
United States, Massachusetts
Boston, Massachusetts, United States
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company
Additional Information:
Layout table for additonal information
Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00046696    
Other Study ID Numbers: NM-103
First Posted: October 2, 2002    Key Record Dates
Last Update Posted: May 20, 2015
Last Verified: May 2015
Keywords provided by Sanofi:
Cancer Alternative Therapies
Living with Cancer